Literature DB >> 21466617

Renin-Angiotensin-aldosterone system in diabetes and hypertension.

Willa A Hsueh1, Kathleen Wyne.   

Abstract

Activation of the renin-angiotensin-aldosterone system (RAAS) is the primary etiologic event in the development of hypertension in people with diabetes mellitus. Modulation of the RAAS has been shown to slow the progression and even cause regression of the microvascular and macrovascular complications associated with diabetes mellitus. Early pharmacotherapy with agents that decrease RAAS activation in the adipose tissue have had a dramatic impact on the prevalence of diabetes related complications. Recent data show that preventing the development of "angry fat" can prevent not just hypertension but also type 2 diabetes mellitus and its associated complications. This review updates what is known about angry fat and the role of RAAS inhibition in preventing the metabolic sequelae of local RAAS activation.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21466617      PMCID: PMC8673350          DOI: 10.1111/j.1751-7176.2011.00449.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  110 in total

1.  Association between dietary factors and plasma adiponectin concentrations in men.

Authors:  Tobias Pischon; Cynthia J Girman; Nader Rifai; Gokhan S Hotamisligil; Eric B Rimm
Journal:  Am J Clin Nutr       Date:  2005-04       Impact factor: 7.045

2.  Effect of ramipril on the incidence of diabetes.

Authors:  Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey Probstfield; George Fodor; Rury R Holman
Journal:  N Engl J Med       Date:  2006-09-15       Impact factor: 91.245

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.

Authors: 
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

5.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Authors:  Nish Chaturvedi; Massimo Porta; Ronald Klein; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Anne Katrin Sjølie
Journal:  Lancet       Date:  2008-09-25       Impact factor: 79.321

6.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction.

Authors:  Abdulrahman K Doughan; David G Harrison; Sergey I Dikalov
Journal:  Circ Res       Date:  2007-12-20       Impact factor: 17.367

9.  Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.

Authors:  Akiko Higuchi; Koji Ohashi; Rei Shibata; Saki Sono-Romanelli; Kenneth Walsh; Noriyuki Ouchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

10.  Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

Authors:  Johannes F E Mann; Hertzel C Gerstein; Qi-Long Yi; Jörg Franke; Eva M Lonn; Byron J Hoogwerf; Andrew Rashkow; Salim Yusuf
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

View more
  32 in total

1.  A MicroRNA Cluster miR-23-24-27 Is Upregulated by Aldosterone in the Distal Kidney Nephron Where it Alters Sodium Transport.

Authors:  Xiaoning Liu; Robert S Edinger; Christine A Klemens; Yu L Phua; Andrew J Bodnar; William A LaFramboise; Jacqueline Ho; Michael B Butterworth
Journal:  J Cell Physiol       Date:  2017-01-05       Impact factor: 6.384

2.  A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease.

Authors:  Daria V Ilatovskaya; Gregory Blass; Oleg Palygin; Vladislav Levchenko; Tengis S Pavlov; Michael N Grzybowski; Kristen Winsor; Leonid S Shuyskiy; Aron M Geurts; Allen W Cowley; Lutz Birnbaumer; Alexander Staruschenko
Journal:  J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 10.121

Review 3.  Mega clinical trials which have shaped the RAS intervention clinical practice.

Authors:  Rainer Düsing
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-06

4.  Neurocardiological differences between musicians and control subjects.

Authors:  J L I Burggraaf; T W Elffers; F M Segeth; F M C Austie; M B Plug; M G J Gademan; A C Maan; S Man; M de Muynck; T Soekkha; A Simonsz; E E van der Wall; M J Schalij; C A Swenne
Journal:  Neth Heart J       Date:  2013-04       Impact factor: 2.380

Review 5.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Aldosterone regulates microRNAs in the cortical collecting duct to alter sodium transport.

Authors:  Robert S Edinger; Claudia Coronnello; Andrew J Bodnar; Mariana Labarca; Vivek Bhalla; William A LaFramboise; Panayiotis V Benos; Jacqueline Ho; John P Johnson; Michael B Butterworth
Journal:  J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 10.121

7.  Direct renin inhibition improves parasympathetic function in diabetes.

Authors:  R E Maser; M J Lenhard; P Kolm; D G Edwards
Journal:  Diabetes Obes Metab       Date:  2012-09-09       Impact factor: 6.577

Review 8.  Midkine in nephrogenesis, hypertension and kidney diseases.

Authors:  Waichi Sato; Yuka Sato
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.

Authors:  C S Oxlund; C Cangemi; J E Henriksen; I A Jacobsen; J Gram; K Schousboe; L Tarnow; W S Argraves; L M Rasmussen
Journal:  J Hum Hypertens       Date:  2014-04-17       Impact factor: 3.012

10.  The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient.

Authors:  Graziano Riccioni
Journal:  Ther Adv Endocrinol Metab       Date:  2013-10       Impact factor: 3.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.